Alps Group Inc officer Poh Chit Laa has filed an initial statement of beneficial ownership. The filing shows direct ownership of 2,000 Ordinary Shares as of March 18, 2026. This Form 3 does not report any recent purchase, sale, or option exercise, only the existing share position.
Alps Group Inc director Chua Boon Ping filed an initial ownership report showing a direct holding of 150,000 Ordinary Shares. This Form 3 does not record a new purchase or sale but establishes the director’s existing equity stake and confirms direct ownership of these shares.
Alps Group Inc director Chew Yoke Ling has filed an initial ownership report showing a substantial equity stake in the company. The Form 3 discloses direct ownership of 6,882,720 Ordinary Shares as of the reported date. This filing records existing holdings and does not reflect any new buy or sell transaction.
Alps Group Inc executive Cheing Lye-Ping, the Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, indicating no insider trading activity is disclosed in this excerpt.
Alps Group Inc director Mohamed Suleiman bin has filed an initial ownership report on Form 3. This filing establishes his status as a director of the company and indicates that there are currently no reportable transactions or derivative positions listed in the submission.
Alps Group Inc executive Manickam Ravichandran, the Chief Scientific Officer, has filed an initial insider ownership report. The filing shows direct ownership of 20,000 Ordinary Shares, establishing his reported equity stake in the company but not reflecting any recent buy or sell transaction.
Alps Group Inc executive Low Wei Sim, the Chief Operating Officer, has filed an initial ownership report showing a direct holding of 821,083 Ordinary Shares. This filing is a Form 3, which records the officer’s existing stake and does not reflect a new buy or sell transaction.
Alps Group Inc director and Chief Executive Officer Tham Seng Kong filed an initial ownership report showing a substantial direct stake in the company. The filing reports beneficial ownership of 77,144,380 Ordinary Shares, confirming his status as a major, more than ten percent, shareholder.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.
Alps Group Inc reports a potential expansion of its exosome-related pipeline beyond its CELESOME(+) programme, based on a newly published retrospective clinical case series of nebulized human umbilical cord mesenchymal stem cell-derived exosomes in patients with asthma and chronic obstructive pulmonary disease.
The peer-reviewed report describes investigational, once-weekly inhaled dosing over five weeks using a medical-grade nebulizer, with observations that included improved pulmonary function, stable inflammatory markers, and no significant adverse effects. Management emphasizes these findings are preliminary and that larger, controlled studies are required, with no assurances on eventual clinical success or regulatory approval.